These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35201894)

  • 21. Editorial Comment: Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography.
    Teles SB; Sanchez-Salas R; Carneiro A
    Int Braz J Urol; 2023; 49(1):155-157. PubMed ID: 36512465
    [No Abstract]   [Full Text] [Related]  

  • 22.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
    J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
    Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M
    Eur Urol; 2023 May; 83(5):405-412. PubMed ID: 36935345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography.
    Veerman H; Donswijk M; Bekers E; Bodar YJL; Meijer D; van Moorselaar RJA; Oprea-Lager DE; van der Noort V; van Leeuwen PJ; Vis AN; van der Poel HG
    BJU Int; 2022 Dec; 130(6):750-753. PubMed ID: 36117468
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
    Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
    Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
    [No Abstract]   [Full Text] [Related]  

  • 27. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with
    Pienta KJ; Gorin MA; Rowe SP; Carroll PR; Pouliot F; Probst S; Saperstein L; Preston MA; Alva AS; Patnaik A; Durack JC; Stambler N; Lin T; Jensen J; Wong V; Siegel BA; Morris MJ
    J Urol; 2021 Jul; 206(1):52-61. PubMed ID: 33634707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer].
    Li Y; Liu B; Yuan Y; Qin W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2022 Dec; 39(6):1263-1268. PubMed ID: 36575097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography.
    Veerman H; Donswijk M; Bekers E; Olde Heuvel J; Bodar YJL; Boellaard TN; van Montfoort ML; van Moorselaar RJA; Oprea-Lager DE; van Leeuwen PJ; Vis AN; van der Poel HG
    BJU Int; 2022 Mar; 129(3):314-317. PubMed ID: 34854204
    [No Abstract]   [Full Text] [Related]  

  • 30. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confirming and Refining Our Existing Postoperative Treatment Strategies Through the Use of Novel Prostate-Specific Positron Emission Tomography (PET) Imaging.
    Hall WA; Lawton CAF
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):118-119. PubMed ID: 36526378
    [No Abstract]   [Full Text] [Related]  

  • 32. [Recent progress of positron radionuclide labeled small molecule inhibitors of prostate specific membrane antigen for PET/CT imaging of prostate cancer].
    Pan L; Wu X; Diao W; Li L
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2020 Apr; 37(2):219-224. PubMed ID: 32329272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
    Menzel P; Chang A
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):261-262. PubMed ID: 31047622
    [No Abstract]   [Full Text] [Related]  

  • 34.
    Lopci E; Saita A; Lazzeri M; Lughezzani G; Colombo P; Buffi NM; Hurle R; Marzo K; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Lista G; Cardone P; Castello A; Maffei D; Balzarini L; Chiti A; Guazzoni G; Casale P
    J Urol; 2018 Jul; 200(1):95-103. PubMed ID: 29409824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer.
    O'Brien JS; McVey A; Kelly BD; Jenjitranant P; Buteau J; Hofman MS; Kasivisvanithan V; Eapen R; Moon D; Murphy DG; Lawrentschuk N
    BJU Int; 2022 Nov; 130 Suppl 3():8-10. PubMed ID: 35574991
    [No Abstract]   [Full Text] [Related]  

  • 36. Imaging of Prostate Cancer Using
    Singh A; Kulkarni HR; Baum RP
    PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
    Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
    J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
    Madan RA; Mena E; Lindenberg L; Choyke PL
    J Clin Oncol; 2022 Sep; 40(26):3015-3019. PubMed ID: 35658513
    [No Abstract]   [Full Text] [Related]  

  • 40. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
    van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
    J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.